Search Results - "Labopin M"

Investigating covariate-by-centre interaction in survival data.

Authors: Biard, L. Labopin, M. Chevret, S. et al.

Source: Statistical Methods in Medical Research. Mar2018, Vol. 27 Issue 3, p920-932. 13p.

In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?

Authors: Peffault de Latour, R Labopin, M Cornelissen, J et al.

Source: Bone Marrow Transplantation. Nov2015, Vol. 50 Issue 11, p1411-1415. 5p. 2 Charts, 1 Graph.

Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia.

Authors: Ruggeri, A Labopin, M Sanz, G et al.

Source: Leukemia (08876924). Sep2015, Vol. 29 Issue 9, p1891-1900. 10p. 5 Charts, 2 Graphs.

Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.

Authors: Passweg, J R Labopin, M Cornelissen, J et al.

Source: Bone Marrow Transplantation. Aug2015, Vol. 50 Issue 8, p1063-1068. 6p. 3 Charts, 2 Graphs.

Long-term persistence of the immune response to antipneumococcal vaccines after Allo-SCT: 10-year follow-up of the EBMT-IDWP01 trial.

Authors: Cordonnier, C Labopin, M Robin, C et al.

Source: Bone Marrow Transplantation. Jul2015, Vol. 50 Issue 7, p978-983. 6p. 3 Charts, 1 Graph.

Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission.

Authors: Versluis, J Labopin, M Niederwieser, D et al.

Source: Leukemia (08876924). Jan2015, Vol. 29 Issue 1, p51-57. 7p.

Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT.

Authors: Kharfan-Dabaja, M A Labopin, M Bazarbachi, A et al.

Source: Bone Marrow Transplantation. Sep2014, Vol. 49 Issue 9, p1170-1175. 6p. 4 Charts, 2 Graphs.

Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT.

Authors: Czerw, T Labopin, M Gorin, N-C et al.

Source: Bone Marrow Transplantation. Jul2014, Vol. 49 Issue 7, p950-954. 5p.

Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome.

Authors: Nagler, A Labopin, M Berger, R et al.

Source: Bone Marrow Transplantation. May2014, Vol. 49 Issue 5, p628-633. 6p.

A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality.

Authors: Labopin, M Gorin, N-C Polge, E et al.

Source: Bone Marrow Transplantation. Mar2014, Vol. 49 Issue 3, p376-381. 6p.

Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Authors: Chevallier, P Labopin, M Milpied, N et al.

Source: Bone Marrow Transplantation. Mar2014, Vol. 49 Issue 3, p361-365. 5p.

Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation

Authors: Baron, F Labopin, M Blaise, D et al.

Source: Bone Marrow Transplantation. Mar2014, Vol. 49 Issue 3, p389-396. 8p.

Allogeneic matched-sibling hematopoietic cell transplantation for AML: comparable outcomes between Eastern Mediterranean (EMBMT) and European (EBMT) centers.

Authors: Bazarbachi, A Labopin, M Ghavamzadeh, A et al.

Source: Bone Marrow Transplantation. Aug2013, Vol. 48 Issue 8, p1065-1069. 5p. 3 Charts, 2 Graphs.

The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT.

Authors: Giebel, S Labopin, M Mohty, M et al.

Source: Bone Marrow Transplantation. Feb2013, Vol. 48 Issue 2, p238-242. 5p. 2 Charts, 1 Graph.

Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.

Authors: Baron, F Labopin, M Niederwieser, D et al.

Source: Leukemia (08876924). Dec2012, Vol. 26 Issue 12, p2462-2468. 7p. 2 Charts, 4 Graphs.

Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT.

Authors: Chevallier, P Labopin, M Milpied, N et al.

Source: Bone Marrow Transplantation. Nov2012, Vol. 47 Issue 11, p1442-1447. 6p. 3 Charts, 3 Graphs.

Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT.

Authors: Spyridonidis, A Labopin, M Schmid, C et al.

Source: Leukemia (08876924). Jun2012, Vol. 26 Issue 6, p1211-1217. 7p. 5 Charts, 2 Graphs.

A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study.

Authors: Chevallier, P. Labopin, M. Turlure, P. et al.

Source: Leukemia (08876924). Jun2011, Vol. 25 Issue 6, p939-944. 6p. 5 Charts, 2 Graphs.

Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia.

Authors: Craddock, C. Labopin, M. Pillai, S. et al.

Source: Leukemia (08876924). May2011, Vol. 25 Issue 5, p808-813. 6p. 2 Charts, 2 Graphs.

Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire.

Authors: Mohty, M. Labopin, M. Balère, M. L. et al.

Source: Leukemia (08876924). Nov2010, Vol. 24 Issue 11, p1867-1874. 8p. 4 Charts, 2 Graphs.